摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2'R,3S,4S,5R)-(-)-anhydrohomoharringtonine | 245085-91-0

中文名称
——
中文别名
——
英文名称
(2'R,3S,4S,5R)-(-)-anhydrohomoharringtonine
英文别名
anhydrohomoharringtonine;[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] (2R)-2-(2-methoxy-2-oxoethyl)-6,6-dimethyloxane-2-carboxylate
(2'R,3S,4S,5R)-(-)-anhydrohomoharringtonine化学式
CAS
245085-91-0
化学式
C29H37NO8
mdl
——
分子量
527.615
InChiKey
NYGKGGIFRQFDRB-JFIAXGOJSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    608.4±55.0 °C(Predicted)
  • 密度:
    1.31±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.8
  • 重原子数:
    38
  • 可旋转键数:
    7
  • 环数:
    6.0
  • sp3杂化的碳原子比例:
    0.66
  • 拓扑面积:
    92.8
  • 氢给体数:
    0
  • 氢受体数:
    9

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety
    摘要:
    (2'R,3S,4S,5R)-(-)-齐墩果酸甲酯 2 由 cephalotaxine 直接酯化制得,采用适当取代的四氢吡喃甲酸的活化形式作为立体紧凑的手性侧链前体,随后通过选择性开环得到相应的 (2'R,3S,4S,5R)-(-)-anhydrohomoharringtonine 6。干酰基部分的两个对映体通过以下两种方法制备:一种方法是对适当取代的烯基 α-酮酯 7 进行不对称 α-羟基烷基化,然后进行酸性环化;另一种方法是通过对 (-)-金鸡纳碱形成非对映异构体来分离对应的外消旋混合物。外消旋 cephalotaxine 以及其两个对映体均由天然的部分外消旋的 (-)-cephalotaxine 1 制得。版权 © 1999 Elsevier Science Ltd,保留所有权利。
    DOI:
    10.1016/s0040-4039(99)00327-5
  • 作为产物:
    参考文献:
    名称:
    The first semi-synthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety
    摘要:
    (2'R,3S,4S,5R)-(-)-齐墩果酸甲酯 2 由 cephalotaxine 直接酯化制得,采用适当取代的四氢吡喃甲酸的活化形式作为立体紧凑的手性侧链前体,随后通过选择性开环得到相应的 (2'R,3S,4S,5R)-(-)-anhydrohomoharringtonine 6。干酰基部分的两个对映体通过以下两种方法制备:一种方法是对适当取代的烯基 α-酮酯 7 进行不对称 α-羟基烷基化,然后进行酸性环化;另一种方法是通过对 (-)-金鸡纳碱形成非对映异构体来分离对应的外消旋混合物。外消旋 cephalotaxine 以及其两个对映体均由天然的部分外消旋的 (-)-cephalotaxine 1 制得。版权 © 1999 Elsevier Science Ltd,保留所有权利。
    DOI:
    10.1016/s0040-4039(99)00327-5
点击查看最新优质反应信息

文献信息

  • [EN] DIOXOLANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF HOMOHARRINGTONINE<br/>[FR] INTERMÉDIAIRE DE DIOXOLANONE UTILE DANS LA SYNTHÈSE DE L'HOMOHARRINGTONINE
    申请人:INDENA SPA
    公开号:WO2018019549A1
    公开(公告)日:2018-02-01
    The invention discloses 2-((2R,4R)-4-(4-(benzyloxy)-4-methylpent-2-yn-1-yl)-2-(tert-butyl)-5-oxo-1,3-dioxolan-4-yl)acetic acid of formula (XIX), a process for its preparation and processes for its conversion into enantiomerically pure (R)-2-(2-methoxy-2-oxoethyl)-6,6-dimethyltetrahydro-2H-pyran-2-carboxylic acid of formula (I), a molecule useful for the synthesis of Homoharringtonine.
    该发明公开了式(XIX)的2-((2R,4R)-4-(4-(苄氧基)-4-甲基戊-2-炔-1-基)-2-(叔丁基)-5-氧代-1,3-二氧杂环戊-4-基)乙酸,其制备方法以及将其转化为式(I)的对映纯(R)-2-(2-甲氧基-2-氧代乙基)-6,6-二甲基四氢-2H-吡喃-2-羧酸的方法,该分子可用于合成吉非替林。
  • Cephalotaxane derivatives and their processes of preparation and purification
    申请人:Chemgenex Pharmaceuticals, Inc.
    公开号:US07842687B2
    公开(公告)日:2010-11-30
    The present invention concerns a new general process for asymmetric hemisynthesis of harringtonines and their analogs, that are alkaloids used in chemotherapy. This process comprises direct esterification of a natural cephalotaxine with an acylating compound constituted of a side chain precursor which backbone and functionalization are entirely preformed. The invention also concerns a natural, synthetic or semi-synthetic harringtonines including their tautomeric forms and their salts of the following formula: wherein n=2 (i.e. harringtonine) or n=3 (i.e. homoharringtonine), in which the total content of impurities, possibly including enantiomeric forms, is lower than 1%, and/or the content of the major impurity is lower than 0.9%, and/or the chromatographic assay exhibits a harringtonines content higher than 97.5%.
    本发明涉及一种新的不对称半合成哈林顿碱及其类似物的通用过程,这些生物碱用于化疗。该过程包括将天然头孢松碱直接酯化为一个酰化化合物,该酰化化合物由一个侧链前体组成,其骨架和功能化已完全形成。本发明还涉及以下式子的天然、合成或半合成的哈林顿碱及其互变异构体和盐:其中n = 2(即哈林顿碱)或n = 3(即同型哈林顿碱),其中可能包括对映异构体的杂质总含量低于1%,主要杂质的含量低于0.9%,或色谱分析显示哈林顿碱含量高于97.5%。
  • Enantioselective semisynthesis of novel cephalotaxine esters with potent antineoplastic activities against leukemia
    作者:Yujian Yang、Qiuchun Yu、Lean Hu、Botao Dai、Ruxi Qi、Yu Chang、Qingwen Zhang、Zhang Zhang、Yingjun Li、Xumu Zhang
    DOI:10.1016/j.ejmech.2022.114731
    日期:2022.12
    leukemia cells. In this study, a method for hydrogenation of β-substituted itaconic acid monoesters with chiral Ru[DTBM-SegPhos](OAc)2 was developed. This metal-catalyzed asymmetric hydrogenation enabled the convenient semisynthesis of novel cephalotaxine derivatives with chiral 2′-substituted-succinic acid 4-mono-methyl esters as side chains. The preliminary structure-activity relationship (SAR) of
    高三尖杉酯碱 (HHT, 1 ) 为代表的头孢紫杉醇类生物碱 (CTA) 对不同类型的白血病细胞显示出强大的功效。在这项研究中,开发了一种用手性 Ru[DTBM-SegPhos](OAc) 2氢化 β-取代衣康酸单酯的方法。这种属催化的不对称氢化能够方便地半合成具有手性 2'-取代-琥珀酸 4-单甲酯作为侧链的新型头孢紫杉醇生物。研究了化合物抗肿瘤活性的初步构效关系(SAR)。最终,我们发现了化合物10b对白血病具有有效的抗肿瘤活性,对一组癌细胞具有广泛的抗癌活性。我们的研究提供了一个高度对映选择性的过程,能够半合成头孢紫杉醇生物,这对于在科学基础上进一步研究很有趣。
  • DIOXOLANONE INTERMEDIATE USEFUL IN THE SYNTHESIS OF HOMOHARRINGTONINE
    申请人:INDENA S.p.A.
    公开号:EP3275875A1
    公开(公告)日:2018-01-31
    The invention discloses 2-((2R,4R)-4-(4-(benzyloxy)- 4-methylpent-2-yn-1-yl)-2-(tert-butyl) -5-oxo-1,3-dioxolan-4-yl)acetic acid of formula (XIX), a process for its preparation and processes for its conversion into enantiomerically pure (R)-2-(2-methoxy-2-oxoethyl)-6,6-dimethyltetrahydro-2H-pyran-2-carboxylic acid of formula (I), a molecule useful for the synthesis of Homoharringtonine.
    本发明公开了式(XIX)的2-((2R,4R)-4-(4-(苄氧基)-4-甲基戊-2-炔-1-基)-2-(叔丁基)-5-氧代-1,3-二氧戊环-4-基)乙酸、一种制备方法和将其转化为式(I)的对映体纯的(R)-2-(2-甲氧基-2-氧代乙基)-6,6-二甲基四氢-2H-吡喃-2-羧酸的方法,该分子可用于合成高卤素宁。
  • WO9948894A1
    申请人:——
    公开号:——
    公开(公告)日:——
查看更多

同类化合物

高三尖杉酯碱酰胺 高三尖杉酯碱 氧桥三尖杉碱 异三尖杉酯碱 双(去甲基)-脱氧三尖杉酯碱 去甲基三尖杉酮碱 去氧哈林通碱 乙酰三尖杉碱 三尖杉酯碱 三尖杉酯碱 三尖杉碱 4-羟基三尖杉碱 4'-去甲基高三尖杉酯碱 (1S,3aR)-1,5,6,8,9,14bbeta-六氢-2-甲氧基-4H-环戊并[a][1,3]二氧杂环戊并[4,5-H]吡咯并[2,1-b][3]苯并氮杂卓-1alpha,9alpha-二醇 (-)-脱水三尖杉酯碱 (2S,3R,4S,5S,7R)-2,3-dihydroxy-7-methyl-cephalotaxan-8-one (2R,3S,4S,5S)-2,3-dihydroxy-8-oxocephalotaxane (+/-)-D-homocephalotaxine Desmethyldiacetyl-cephalotaxin (3aα,4S*,10β,15bβ,15cα)-(+/-)-10-acetoxy-3a,4,6,7,9,10,15b,15c-octahydro-2,2-dimethyl-5H-<1,3>dioxolo<4,5-h>-1,3-dioxolo<4,5>cyclopenta<1,2-a>pyrrolo<2,1-b><3>benzazepine Cephalotaxyl 6,6-dimethyl-5,6-dihydropyran-1-carboxylate 3t-phenyl-acrylic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester 6-O-(4-methylimidazole-3-carbonyl)2,6-diacetylhomoharringtonine 6-O-(2-chloropyridin-3-carbonyl)2,6-diacetylhomoharringtonine (Ξ)-methylsuccinic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 6-O-(phenylacetyl)2,6-diacetylhomoharringtonine 6-O-(furan-2-carbonyl)2,6-diacetylhomoharringtonine succinic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester methyl ester O-3-[(2R)-2,6-dihydroxy-2-(2'-cyclohexaneamino-2'-oxoethyl)-6-methylheptanoyl]cephalotaxine (2R,7R)-17,19-dioxa-11-azapentacyclo[12.7.0.02,7.07,11.016,20]henicosa-1(21),4,12,14,16(20)-pentaen-10-one Acetic acid 6-((1aR,2aS,5aR,6S,6aS)-5-methyl-4-oxo-octahydro-1-oxa-5-aza-cyclopropa[f]inden-6-yl)-benzo[1,3]dioxol-5-ylmethyl ester (Ξ)-(3-methyl-butyl)-succinic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-[4-methyl-4-(4-methyl-1,3-thiazole-5-carbonyl)oxypentyl]-2-(4-methyl-1,3-thiazole-5-carbonyl)oxybutanedioate 3,8-dioxocephalotax-1-ene furan-3,4-dicarboxylic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester methyl ester 2α,3α-dihydroxycephalotaxan-8-one 2,3-dehydrocephalotaxan-8-one 1-O-[(2S,3S,6R)-4-methoxy-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),4,13,15(19)-tetraen-3-yl] 4-O-methyl (2R)-2-[4-(cyclohexanecarbonyloxy)-4-methylpentyl]-2-hydroxybutanedioate 2α,3α-epoxycephalotaxan-8-one [(2S,3R,4S,6S)-3-acetyloxy-9-oxo-16,18-dioxa-10-azapentacyclo[11.7.0.02,6.06,10.015,19]icosa-1(20),13,15(19)-trien-4-yl] acetate (3-methyl-butyl)-butenedioic acid 1-((3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl) ester 4-methyl ester benzyl ((2S,3S,3aR)-2,3-dihydroxy-2,3,5,6,8,9-hexahydro-4H-[1,3]dioxolo[4',5':4,5]benzo[1,2-d]cyclopenta[b]pyrrolo[1,2-a]azepin-1-yl) carbonate 3t-(4-nitro-phenyl)-acrylic acid (3aR)-2-methoxy-(3arC4,14bc)-1,5,6,8,9,14b-hexahydro-4H-cyclopenta[b][1,3]dioxolo[4',5':4,5]benzo[1,2-d]pyrrolo[1,2-a]azepin-1t-yl ester (2R,3S,4S,5S)-2-(tert-butyldimethylsililoxy)-3-hydroxy-8-oxocephalotaxane